FDA
-
-
-
-
-
-
-
Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therap
-
-
-
-
-
-
-
Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy
-
-
-
-
-
-
-
Biohaven to Present R&D Day at Yale School of Management
-
-
-
-
-
-
-
Biohaven's Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy
-
-
-
-
-
-
-
Biohaven Sets New Course with $258 Million in Cash, a Proven Team and Deep Pipeline to Continue its Journey to Advance Science for Patients
-
-
-
-
-
-
-
Freedom Biosciences Emerges from Stealth with $10.5 Million Seed Financing to Develop Next-Generation Ketamine and Psychedelic-based Mental Health Treatments
-
-
-
-
-
-
-
Biohaven Presents New Migraine Data at 64th Annual Scientific Meeting of the American Headache Society, including First of Its Kind Study for NurtecĀ® ODT (rimegepant), and Complete Phase 3 Data for Z
-
322,238 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

